PMID- 19448594
OWN - NLM
STAT- MEDLINE
DCOM- 20091009
LR  - 20230210
IS  - 1530-0285 (Electronic)
IS  - 0893-3952 (Linking)
VI  - 22
IP  - 8
DP  - 2009 Aug
TI  - Fluorescence in situ hybridization as a tool for microstaging in malignant 
      melanoma.
PG  - 989-95
LID - 10.1038/modpathol.2009.72 [doi]
AB  - Up to 30-50% of melanomas arise in association with a nevus. Accurately defining, 
      the nevus from the melanoma can significantly affect microstaging. Recently, we 
      showed that a targeted fluorescence in situ hybridization (FISH) assay could 
      distinguish between benign nevi and melanoma with a sensitivity of 87% and 
      specificity of 95%. In this study, we evaluated the potential of this same assay 
      for use in the microstaging of melanoma. We performed FISH on 36 cases of 
      melanoma occurring in association with a nevus and 6 cases of nevoid melanoma 
      with deep dermal involvement. In the melanomas with associated benign nevi, FISH 
      enumeration was performed separately on the histologically malignant and benign 
      components. In the nevoid melanomas, FISH was performed on the deep dermal areas. 
      On the basis of the criteria developed in our earlier studies, we determined the 
      sensitivity of the assay within the malignant areas and the specificity within 
      the benign areas of melanomas with associated nevi. In addition, we evaluated the 
      sensitivity and specificity within a group of six nevoid melanomas with deep 
      dermal involvement. Among melanomas with associated nevi, 28 of 36 cases (78%) 
      tested positively in the histologically malignant areas. The benign nevus 
      components were uniformly negative for all criteria. Six of six nevoid melanomas 
      (100%) tested positively in the deep dermal area. FISH analysis with probes 
      targeting 6p25, 6q23, 11q13 and CEP6 can effectively discriminate the malignant 
      and benign components of melanomas with associated nevi and can be used as an 
      adjunctive tool for microstaging. The assay has high sensitivity for the 
      malignant areas of nevus-associated melanomas and outstanding specificity for the 
      benign areas. The sensitivity is independent of the morphological features, and 
      the assay performs well in nevoid melanoma cases.
FAU - Newman, Marissa D
AU  - Newman MD
AD  - Department of Dermatology, The Feinberg School of Medicine, Northwestern 
      University, Chicago, IL 60611, USA.
FAU - Lertsburapa, Terakeith
AU  - Lertsburapa T
FAU - Mirzabeigi, Marjan
AU  - Mirzabeigi M
FAU - Mafee, Mariam
AU  - Mafee M
FAU - Guitart, Joan
AU  - Guitart J
FAU - Gerami, Pedram
AU  - Gerami P
LA  - eng
PT  - Journal Article
DEP - 20090515
PL  - United States
TA  - Mod Pathol
JT  - Modern pathology : an official journal of the United States and Canadian Academy 
      of Pathology, Inc
JID - 8806605
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence
MH  - Male
MH  - Melanoma/genetics/*pathology
MH  - Middle Aged
MH  - Neoplasm Staging/*methods
MH  - Nevus, Pigmented/genetics/*pathology
MH  - Precancerous Conditions/pathology
MH  - Sensitivity and Specificity
MH  - Skin Neoplasms/genetics/*pathology
MH  - Young Adult
EDAT- 2009/05/19 09:00
MHDA- 2009/10/10 06:00
CRDT- 2009/05/19 09:00
PHST- 2009/05/19 09:00 [entrez]
PHST- 2009/05/19 09:00 [pubmed]
PHST- 2009/10/10 06:00 [medline]
AID - S0893-3952(22)02482-6 [pii]
AID - 10.1038/modpathol.2009.72 [doi]
PST - ppublish
SO  - Mod Pathol. 2009 Aug;22(8):989-95. doi: 10.1038/modpathol.2009.72. Epub 2009 May 
      15.